Display options
Cite
Fan YX, Liang ZX, Liu QZ, et al. Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer. Exp Ther Med. 2017;13(3):989-994doi: 10.3892/etm.2017.4079.
Fan, Y. X., Liang, Z. X., Liu, Q. Z., Xiao, H., Li, K. B., & Wu, J. Z. (2017). Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer. Experimental and therapeutic medicine, 13(3), 989-994. https://doi.org/10.3892/etm.2017.4079
Fan, Yi-Xiang, et al. "Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer." Experimental and therapeutic medicine vol. 13,3 (2017): 989-994. doi: https://doi.org/10.3892/etm.2017.4079
Fan YX, Liang ZX, Liu QZ, Xiao H, Li KB, Wu JZ. Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer. Exp Ther Med. 2017 Mar;13(3):989-994. doi: 10.3892/etm.2017.4079. Epub 2017 Jan 23. PMID: 28450931; PMCID: PMC5403560.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Mar;13(3):989-994. doi: 10.3892/etm.2017.4079. Epub 2017 Jan 23.

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer.

Experimental and therapeutic medicine

Yi-Xiang Fan, Zhi-Xin Liang, Qing-Zhu Liu, Han Xiao, Ke-Bin Li, Ji-Zhen Wu

Affiliations

  1. Department of Nuclear Medicine, Second People's Hospital, Guangzhou, Guangdong 510317, P.R. China.

PMID: 28450931 PMCID: PMC5403560 DOI: 10.3892/etm.2017.4079

Abstract

The aim of the present study was to clarify whether the cell penetrating peptide of sodium-iodide symporter (NIS) has an effect on the I-131 radiotherapy of thyroid cancer. Firstly, we combined the HIV-1 TAT peptide (a cell penetrating peptide, dTAT) and established a nanoparticle vector (dTAT NP) to study the delivery efficiency of this cell-penetrating strategy for tumor-targeted gene delivery. dTAT NP was transfected into cultured TPC-1 cells as a model to study the effects of I-131 radiotherapy on thyroid cancer. Reverse transcription-quantitative polymerase chain reaction and western blotting results showed that the mRNA and protein expression levels of NIS in the transfected TPC-1 cells were substantially higher than in the negative control cells. MTT and flow cytometric analyses demonstrated that the cell growth and apoptosis rates of the TPC-1 cells were significantly inhibited and activated, respectively, by treatment with dTAT NP. The results of DAPI staining showed that treatment with dTAT NP visibly increased the nuclear apoptosis rate of the TPC-1 cells. The effect of dTAT NP on TPC-1 cells was associated with the promotion of caspase-3 and downregulation of the PI3K/Akt signaling pathway. In summary, the present data provide a pre-clinical proof-of-concept for a novel gene delivery system that efficiently delivers NIS to the targeted cancer cells and presents a satisfactory efficacy. This approach may offer an effective strategy for improving thyroid cancer gene therapy.

Keywords: caspase-3; cell penetrating peptide of sodium-iodide symporter; phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B; thyroid cancer

References

  1. Cancer. 2016 Dec 15;122(24):3856-3864 - PubMed
  2. Gene Ther. 2007 Dec;14 (24):1731-8 - PubMed
  3. Acta Cytol. 2006 Sep-Oct;50(5):560-2 - PubMed
  4. Nucl Med Commun. 2001 Jun;22(6):673-8 - PubMed
  5. Methods. 2001 Dec;25(4):402-8 - PubMed
  6. Hell J Nucl Med. 2010 Sep-Dec;13(3):208-12 - PubMed
  7. J Transl Med. 2013 Mar 22;11:74 - PubMed
  8. Int J Clin Exp Pathol. 2013 Sep 15;6(10 ):2112-20 - PubMed
  9. Perm J. 2016 Fall;20(4):22-26 - PubMed
  10. Health Phys. 2015 Mar;108(3):319-25 - PubMed
  11. J Radiol Prot. 2014 Sep;34(3):699-708 - PubMed
  12. BMC Cancer. 2014 Jun 05;14 :405 - PubMed
  13. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1354-62 - PubMed
  14. Hell J Nucl Med. 2013 May-Aug;16(2):103-6 - PubMed
  15. Head Neck. 2016 Dec;38(12 ):1862-1869 - PubMed
  16. Clin Imaging. 2012 May-Jun;36(3):224-7 - PubMed
  17. Eur J Endocrinol. 2015 Oct;173(4):525-40 - PubMed
  18. Cancer Biother Radiopharm. 2007 Apr;22(2):289-95 - PubMed
  19. Oncol Rep. 2015 Apr;33(4):1994-2000 - PubMed
  20. Nanomedicine (Lond). 2015 May;10(10):1539-53 - PubMed
  21. Appl Immunohistochem Mol Morphol. 2013 May;21(3):237-41 - PubMed
  22. Int J Surg. 2015 Apr;16(Pt A):107-12 - PubMed
  23. J Clin Endocrinol Metab. 2000 Aug;85(8):2889-96 - PubMed
  24. Anal Biochem. 2015 Sep 1;484:136-42 - PubMed
  25. J Clin Endocrinol Metab. 2011 Nov;96(11):3326-36 - PubMed
  26. J Photochem Photobiol B. 2015 Jul;148:118-27 - PubMed
  27. Contemp Oncol (Pozn). 2014;18(4):234-40 - PubMed
  28. Horm Metab Res. 2014 May;46(5):313-7 - PubMed
  29. Mol Inform. 2016 Oct;35(10 ):495-505 - PubMed

Publication Types